IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer
This study has been completed.
Sponsor:
Gunma University
Collaborator:
J~pharma
Information provided by:
Gunma University
ClinicalTrials.gov Identifier:
NCT00826033
First received: January 20, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.
The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.
| Condition |
|---|
| Non-Small Cell Lung Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy |
Resource links provided by NLM:
Genetics Home Reference related topics:
lung cancer
MedlinePlus related topics:
Lung Cancer
U.S. FDA Resources
Further study details as provided by Gunma University:
Eligibility| Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
This study was conducted at the Gunma University Hospital.
Criteria
Inclusion Criteria:
- primary lung cancer All patients received first-line chemotherapy
Exclusion Criteria:
- Patients with diabetus mellitus
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00826033
Please refer to this study by its ClinicalTrials.gov identifier: NCT00826033
Locations
| Japan | |
| Gunma University Graduate School of Medicine | |
| Gunma, Japan, 371-8511 | |
Sponsors and Collaborators
Gunma University
J~pharma
More Information
| ClinicalTrials.gov Identifier: | NCT00826033 History of Changes |
| Other Study ID Numbers: |
Mol Imaing 1 |
| Study First Received: | January 20, 2009 |
| Last Updated: | January 20, 2009 |
Keywords provided by Gunma University:
|
Fluorine-18-α-methyltyrosine Positron emission tomography Lung cancer chemotherapy monitoring |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Fluorides alpha-Methyltyrosine Cariostatic Agents Protective Agents Physiological Effects of Drugs Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on September 19, 2017